Literature DB >> 20029463

Cross-immune tolerance: conception and its potential significance on transplantation tolerance.

Yong Zhao1, Xianchang Li.   

Abstract

The diversity of alloreactive T cells in graft rejection and the presence of extensive crossreactivity among alloreactive T cells indicate that the induction of transplantation tolerance may fundamentally alter the size of host T-cell repertoire involved in protective immunity and immune surveillance, especially those that are crossreactive to conventional antigens. We herein highlight the crossreactive nature of alloreactive T cells and the potential risks of altered T-cell repertoire associated with the induction of transplantation tolerance. The possibility that T-cell tolerance to one set of antigens results in their tolerance to other unrelated antigens due to T-cell crossreactivity and/or heterogeneity is defined as 'cross-immune tolerance'. The definition and significance of this concept were discussed in details.

Mesh:

Substances:

Year:  2009        PMID: 20029463      PMCID: PMC4003252          DOI: 10.1038/cmi.2009.101

Source DB:  PubMed          Journal:  Cell Mol Immunol        ISSN: 1672-7681            Impact factor:   11.530


  59 in total

1.  Optimizing a limiting dilution culture system for quantifying the frequency of interleukin-2-producing alloreactive T helper lymphocytes.

Authors:  P I Hornick; P A Brookes; P D Mason; K M Taylor; M H Yacoub; M L Rose; R Batchelor; R I Lechler
Journal:  Transplantation       Date:  1997-08-15       Impact factor: 4.939

2.  A basis for alloreactivity: MHC helical residues broaden peptide recognition by the TCR.

Authors:  C Daniel; S Horvath; P M Allen
Journal:  Immunity       Date:  1998-05       Impact factor: 31.745

Review 3.  A very high level of crossreactivity is an essential feature of the T-cell receptor.

Authors:  D Mason
Journal:  Immunol Today       Date:  1998-09

4.  Resistance to monoclonal antibody-induced CD8+ T-cell depletion in thymectomized MHC class II-deficient mice.

Authors:  Y Zhao; M Sykes
Journal:  Transplantation       Date:  1997-08-15       Impact factor: 4.939

5.  T cells can be activated by peptides that are unrelated in sequence to their selecting peptide.

Authors:  L Ignatowicz; W Rees; R Pacholczyk; H Ignatowicz; E Kushnir; J Kappler; P Marrack
Journal:  Immunity       Date:  1997-08       Impact factor: 31.745

6.  The repertoire of T cells shaped by a single MHC/peptide ligand.

Authors:  L Ignatowicz; J Kappler; P Marrack
Journal:  Cell       Date:  1996-02-23       Impact factor: 41.582

Review 7.  Cryptic T-cell epitopes and their role in the pathogenesis of autoimmune diseases.

Authors:  M G Warnock; J A Goodacre
Journal:  Br J Rheumatol       Date:  1997-11

8.  Cross-reactive memory T cells for Epstein-Barr virus augment the alloresponse to common human leukocyte antigens: degenerate recognition of major histocompatibility complex-bound peptide by T cells and its role in alloreactivity.

Authors:  S R Burrows; S L Silins; R Khanna; J M Burrows; M Rischmueller; J McCluskey; D J Moss
Journal:  Eur J Immunol       Date:  1997-07       Impact factor: 5.532

9.  Heterologous immunity provides a potent barrier to transplantation tolerance.

Authors:  Andrew B Adams; Matthew A Williams; Thomas R Jones; Nozomu Shirasugi; Megan M Durham; Susan M Kaech; E John Wherry; Thandi Onami; J Gibson Lanier; Kenneth E Kokko; Thomas C Pearson; Rafi Ahmed; Christian P Larsen
Journal:  J Clin Invest       Date:  2003-06       Impact factor: 14.808

Review 10.  Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens.

Authors:  W R Heath; C Kurts; J F Miller; F R Carbone
Journal:  J Exp Med       Date:  1998-05-18       Impact factor: 14.307

View more
  1 in total

1.  Bronchus-associated lymphoid tissue-resident Foxp3+ T lymphocytes prevent antibody-mediated lung rejection.

Authors:  Wenjun Li; Jason M Gauthier; Ryuji Higashikubo; Hsi-Min Hsiao; Satona Tanaka; Linh Vuong; Jon H Ritter; Alice Y Tong; Brian W Wong; Ramsey R Hachem; Varun Puri; Ankit Bharat; Alexander S Krupnick; Chyi S Hsieh; William M Baldwin; Francine L Kelly; Scott M Palmer; Andrew E Gelman; Daniel Kreisel
Journal:  J Clin Invest       Date:  2018-12-18       Impact factor: 14.808

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.